Page 64 - MemoriaBBN-Eng

RESEARCH GROUPS

é

ó

íóí
áé
ñí

ú

PROGRAMME:
Nanoparticle and Peptide Chemical Group
Nanomedicine

Lead Researcher
Group Members

STAFF MEMBERS
Albericio Palomera, Fernando
Acosta Crespo, Gerardo Alexis

Farras Torres, Immaculada
Contact:
Pulido Martnez, Daniel

Fund. Priv. Instituto de Recerca Biomedica (IRB).
C/ Josep Samitier, 1-5. Barcelona. ASSOCIATED MEMBERS
Hosta Rigau, Leticia
E-mail: [email protected]
http://www.irbbarcelona.org/index.php/en/research/programmes/chemistry- Pla Queral, Daniel
Royo Expsito, Miriam
and-molecular-pharmacology/combinatorial-chemistry-for-the-discovery-of-
new-compounds/people/fernando-albericio
CONTRIBUTORS
Bruno, Paolo

Lpez Ibez, Alba Main lines of research
Lorente Crivill, Adriana

Mata Chavarria, Alvaro • Design and synthesis of bioactive low molecular weight compounds and peptides.
Melgarejo Daz, Marta
• Dendrimers based on defined units of olidoethylene glycol (OEG) as multifunctio-
Prez Rodrguez , Ral nal systems for the creation of new biomaterials with application to drug delivery

Pulido Villamil, Ximena Carolina and tissue engineering (osteogenesis).
Savina , Svetlana
• Drugs-polymer conjugates based on polyglutamic (PGA) or OEG dendrimers, as
Sisquella Duran, Francesc Xavier nanomedicines for the advanced colorectal cancer treatment. Study of the ouse
Tejeda Montes, Esther
of these platforms on monotherapy and combined therapy .
• Multiple ligands as chemical tools to study various biological processes, for exam-

ple: G protein-coupled receptors (GPCRs) oligomerization.
13
• Design and synthesis of a bicomponent thermoreversible hydrogel platform which 20
combines the bioactive peptide dendrimer decorated hyaluronic acid with the T
R
thermoresponsive hyaluronic acid for developing scaffolds for tissue engineering PO
with application to regenerative medicine (bone and cartilague regeneration).
E
L R
• Development of protein drug delivery systems (PEGylation, peptide functionali- A
zed nanovesicles) for substitutive therapy (ie: Fabry disease).
NU
N
• Design and synthesis of gamma peptides with capacity to cross biological ba- A
/
rriers, such as the cytoplasm membrane of eukaryotic cells and parasites (Leish- BN
mania) and the blood brain barrier (BBB).
B
R-
• Development of new target peptides for colorectal and triple negative breast BE
CI
cancer tissues.
64
• Vectorized multicomponent nanoparticles as drug delivery systems and modula-

tors of pharmacokinetic properties.